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Summary: The SARS-CoV-2 alpha variant is associated with 62% increased risk of hospitalisation and 
73% increased risk of death, compared to the originally circulating wild type virus in England 


















Background: The SARS-CoV-2 alpha variant (B.1.1.7) is associated with higher transmissibility than 
wild type virus, becoming the dominant variant in England by January 2021. We aimed to describe 
the severity of the alpha variant in terms of the pathway of disease from testing positive to hospital 
admission and death. 
Methods: With the approval of NHS England, we linked individual-level data from primary care with 
SARS-CoV-2 community testing, hospital admission, and ONS all-cause death data. We used testing 
data with S-gene target failure as a proxy for distinguishing alpha and wild-type cases, and stratified 
Cox proportional hazards regression to compare the relative severity of alpha cases compared to 
wild type diagnosed from 16th November 2020 to 11th January 2021.  
Results: Using data from 185,234 people who tested positive for SARS-CoV-2 in the community 
(alpha=93,153; wild-type=92,081), in fully adjusted analysis accounting for individual-level 
demographics and comorbidities as well as regional variation in infection incidence, we found alpha 
associated with 73% higher hazards of all-cause death (aHR: 1.73 (95% CI 1.41 - 2.13; P<.0001)) and 
62% higher hazards of hospital admission (aHR: 1.62 ((95% CI 1.48 - 1.78; P<.0001), compared to 
wild-type virus. Among patients already admitted to ICU, the association between alpha and 
increased all-cause mortality was smaller and the confidence interval included the null (aHR: 1.20 
(95% CI 0.74 - 1.95; P=0.45)).  
Conclusions: The SARS-CoV-2 alpha variant is associated with an increased risk of both 


















The SARS-CoV-2 (COVID-19) variant of concern B.1.1.7, now called the alpha variant, was first 
identified in Kent, UK in autumn 2020.1 Early analysis estimated that alpha is more transmissible 
than the original lineage and it became the dominant strain throughout the UK in early 2021.2 Only a 
small number of alpha cases were originally identified by whole-genome sequencing. Certain PCR 
assays for SARS-CoV-2 that are used in three major laboratories in England do not amplify one of the 
spike protein gene targets in the alpha variant. Spike gene target failure (SGTF) was therefore 
adopted as a proxy for identifying alpha, and has been shown to have more than 95% sensitivity for 
alpha viruses during the period 16th November 2020 – 11th January 2021.3 
While a number of studies have  shown that alpha is associated with an overall higher case fatality 
than the original lineage,4-8 studies specifically restricted to hospitalised patients have shown no 
difference in case fatality.8,9 However, these findings are not necessarily contradictory as alpha may 
cause more severe disease leading to more people needing hospital admission, but may not be any 
more likely than the original lineage to cause death in those who already have severe disease 
requiring hospital care. 
This study aims to bring these elements together in a consolidated analysis, following the pathway of 
disease from infection to hospital admission and death, in order to fully illuminate the association of 




With the approval of NHS England, data were linked, stored and analysed securely within the 
OpenSAFELY electronic health records research platform.10 OpenSAFELY holds electronic health 
records (EHRs) for 58 million individual registrations with a general practitioner (GP) in England, and 
in this study we use a subset of these who are registered at practices using the TPP EHR 
management system, which includes 24 million people, covering 40% of England’s population. 
Primary care data include individual-level coded diagnoses, medications, vaccinations, and 
physiological parameters. These data were linked to key datasets to obtain: 1) SARS-CoV-2 
community testing data through the Second Generation Surveillance System; 2) hospital admission 
data; 3) COVID-19 related intensive care unit (ICU) admission data; 4) all-cause registered deaths 
from the Office for National Statistics (ONS). More information on the OpenSAFELY analytical 
platform and data sources is available in supplement sections 1-3 and supplementary Table S1. 
Study design and population 
We defined our study population as all who tested positive for SARS-CoV-2 in the community with 
data available on SGTF status, between 16 November 2020 and 11 January 2021. During this time 
alpha cases increased from a small minority as a proportion of all diagnosed SARS-CoV-2 infections in 
the UK, to the dominant majority. This period of cross-over from the original lineage to alpha 
presents the ideal cohort for comparison of the relative severity of alpha compared to wild type 
virus. The study period predates the emergence of the delta variant. 
The primary exposure of interest was SGTF status. SGTF was taken as a proxy for identifying the 

















The primary analysis used a Cox proportional hazards regression model stratified by geographic 
region, defined as upper tier local authority area (UTLA).11,12 Stratification by region allowed a 
separate hazard function to be estimated for each region, with parameter estimates estimated over 
the full population. This degree of regional flexibility was included a priori to account for potentially 
non-proportional changes in pandemic incidence over time by region. 
For analysis of all-cause mortality, follow-up began at the date of testing positive in the community 
for SARS-CoV-2 and was censored at 21 April 2021 or 7 days prior to receipt of a vaccination against 
SARS-CoV-2. Since illness which may lead to death would exclude the booking and administration of 
a vaccine, the 7 days prior to vaccination were censored to discount a potential immortal time bias. 
For analysis of hospital admission, follow-up began at the date of testing positive for SARS-CoV-2 and 
was censored at 21 April 2021, the date of deregistration from GP practice, or 7 days prior to receipt 
of a vaccination against SARS-CoV-2. 
For analysis of all-cause mortality among those admitted to hospital, follow-up began at the date of 
hospital admission and was censored at 21 April 2021 or 7 days prior to receipt of a vaccination 
against SARS-CoV-2. In England, the NHS vaccination programme for SARS-CoV-2 began in December 
2020, consequently censoring on vaccination was rare in this study population. A further analysis of 
those admitted to hospital was performed on the population who spent time in the intensive care 
unit (ICU) during their hospital stay. This subset further conditions the population admitted to 
hospital to be those with severe illness who received intensive care. 
Covariate adjustment was informed by consideration of causal pathways using a causal diagram. 
Subgroup analysis of the primary exposure was pre-specified for epidemiological week of SARS-CoV-
2 diagnosis, comorbidity status, ethnicity in five categories, deprivation quintile, and age group.  
Comorbidities were defined as in our prior work,6 as the presence of codes in the patient’s EHR 
indicating diagnoses. All codes and conditions are given in supplement section 4 Table S2. 
A number of pre-specified sensitivity analyses were also performed including censoring all follow-up 
28-days after SARS-CoV-2 diagnosis, restricting to the population with a minimum of 40 days’ follow-
up, and imputing missing data on ethnicity. Further information on analysis methods and full details 
of all pre-specified sensitivity and subgroup analyses is available in the study protocol 
(https://github.com/opensafely/SGTF-CFR-research/tree/master/docs/). 
Absolute risk estimates were calculated from the marginal means of fully adjusted logistic regression 
models with the outcomes death by 28-days after a positive SARS-CoV-2 test, and hospital admission 
by 28-days after a positive SARS-CoV-2 test. In each case, the population was restricted to those who 
had a minimum of 28-days follow-up from the date of their positive SARS-CoV-2 test to the follow-up 
censor. In these models, deaths and hospital admissions beyond 28-days were censored. Vaccination 



















Our study population consists of 185,234 people testing positive for SARS-CoV-2 in the community 
between 16th November 2020 and 11th January 2021 for whom SGTF status was known 
(alpha=93,153; wild type=92,081). In the week beginning 16th November 2020 wild type cases 
accounted for 20,926/22,062 (94.9%) of total cases, by the week beginning 4th January 
29,349/36,821 (79.7%) were alpha. Consequently, median follow-up time was shorter for alpha 
cases (102.0 days (interquartile range (IQR): 62.0-113.0) vs. 109.0 (71.0-136.0)), compared to wild 
type cases. Overall, alpha cases were concentrated in the East (37.5%), London (12.3%), and North 
West (11.0%), reflecting areas where the alpha epidemic began. Wild type cases were mainly from 
Yorkshire and the Humber (25.3%), the East Midlands (20.3%), and North West (16.0%) (Figure 1; 
supplementary Table S3). 
People with the alpha variant were marginally younger overall (median age 37.0 vs. 38.0), with a 
smaller proportion of people aged 70-<80 (2.9% vs. 3.4%) and 80+ (0.9% vs. 1.7%), compared to wild 
type cases. Fewer people infected with the alpha variant had underlying comorbidities (1 
comorbidity (10.4% vs. 11.6%); 2+ comorbidities (2.9% vs. 3.8%)), compared to those infected with 
wild type virus. The proportion of people identified as living in care homes was lower for alpha cases 
(0.1% vs. 0.4%). A lower proportion of people with the alpha variant lived in areas of the most 
deprived SES quintile (16.7% vs. 26.3%), whereas a higher proportion lived in areas of the least 
deprived SES quintile (22.1% vs. 17.4%), compared to people with wild type virus (Figure 1; 
supplementary Table S3). 
 
Case fatality 
985 deaths of any cause were registered by 21st April 2021 (alpha: 500 (0.5%); wild type: 485 
(0.5%)). In fully adjusted analysis, accounting for demographic factors, regional variation, and 
individual-level comorbidities, alpha was associated with 73% increased hazards of death (adjusted 
hazard ratio (aHR): 1.73 (95% confidence interval (CI): 1.41 - 2.13); P<0.0001) when compared to 
wild type (Figure 2). The increased hazard of death for alpha was consistent across all predefined 
subgroups and sensitivity analyses (supplementary Figure S1). 
The absolute risk of death by 28-days post positive SARS-CoV-2 test for people with alpha was low 
for males (0.03% (95% CI: 0.01 - 0.04)) and females (0.01% (0.00 - 0.02)) aged 40 and below in the 
absence of comorbidities. However, the risk of death by 28-days was considerable for males (10.4% 
(7.1 - 13.7)) and females (6.0% (4.0 - 8.0)) aged 85 and over with alpha. In the presence of 2 or more 
comorbidities the risk of death by 28-days for those with alpha was increased for males (0.08% (95% 
CI: 0.02 - 0.13)) and females (0.04% (0.01 - 0.07)) aged 40 and below, and was particularly high for 
males (25.0% (19.5 - 30.4)) and females (15.7% (11.9 - 19.5)) aged 85 and above (Table 1). 
Admission to hospital 
316 of 985 (32.1%) deaths registered in the study occurred without admission to hospital (alpha: 
131; wild type: 185). People who died without hospital admission were older (median age 80.0 (IQR: 
















proportion were resident in a care home (31.6% vs. 6.0%), compared to deaths following admission 
to hospital (Figure 3). 
4,910 people were admitted to hospital following a positive test for SARS-CoV-2 in our dataset 
(alpha: 2,721 (2.9%); wild type: 2,189 (2.4%)). Compared to the full study population, those admitted 
to hospital were older (median age 58.0 vs. 38.0), with more comorbidities (1 comorbidity: 27.4% vs. 
11.0%; 2+ comorbidities: 21.9% vs. 3.4%). Among people admitted to hospital, those with alpha 
were younger (median age 57.0 (IQR: 47.0 - 68.0) vs. 59.0 (48.0 - 72.0)), and had fewer comorbidities 
(2+ comorbidities 19.3% vs. 25.2%), compared to those with wild type (supplementary Table S4). 
In fully adjusted analysis, accounting for demographic factors, regional variation, and individual level 
comorbidities, alpha was associated with 62% increased hazards of hospital admission (aHR: 1.62 
(95% CI: 1.48 - 1.78); P<0.0001) when compared to wild type (Figure 2). The increased hazard of 
hospital admission for alpha was consistent across all predefined subgroups and sensitivity analyses 
(supplementary Figure S2). 
The absolute risk of hospital admission by 28-days post positive SARS-CoV-2 test for those with alpha 
was 1.1% for males (1.1% (95% CI: 1.01 - 1.24)) and 0.7% for females (0.74% (0.67 - 0.82)) aged 40 
and below in the absence of comorbidities. However, the risk of hospitalisation was considerable for 
males (18.1% (14.9 - 21.2)) and females (12.8% (10.4 - 15.1)) aged 85 and above. In the presence of 2 
or more comorbidities the risk of hospital admission for those with alpha was increased for males 
(3.3% (95% CI: 2.8 - 3.8)) and females (2.2% (1.9 - 2.5)) aged 40 and below, and high for males (38.8% 
(34.2 - 43.4)) and females (29.7% (25.7 - 33.8)) aged 85 and above (Table 2). 
 
Case fatality given hospital admission 
There were 669 deaths among people admitted to hospital (alpha: 369 (13.6%); wild type: 300 
(13.7%)). In fully adjusted analysis, accounting for demographic factors, regional variation, and 
individual level comorbidities, alpha was associated with 44% increased hazards of death (aHR: 1.44 
(95% CI: 1.11 - 1.87); P=0.0057) when compared to wild type after conditioning on hospital 
admission (Figure 2). The increased hazard of death for alpha conditional on hospital admission was 
consistent across all predefined subgroups and sensitivity analyses (supplementary Figure S2). 
Among people admitted to hospital, 615/4,910 (12.5%) were admitted to the intensive care unit 
(ICU) (alpha: 344; wild type: 271). Compared to people admitted to hospital, those admitted to ICU 
were of similar age (median age 59.0 vs. 58.0), with a higher proportion having one comorbidity (1 
comorbidity: 31.5% vs. 27.4%; 2+ comorbidities: 19.5% vs. 21.9%). Mortality among those admitted 
to ICU was high (alpha: 147/344 (42.7%); wild type: 99/271 (36.5%)). In fully-adjusted analysis, 
accounting for demographic factors, regional variation, and individual level comorbidities, the 
association between alpha and increased mortality was smaller and the confidence interval included 
the null (aHR: 1.20 (95% CI 0.74 - 1.95; P=0.45), compared to wild type cases after conditioning on 


















This study describes the relative severity of the alpha SARS-CoV-2 variant compared to wild type 
virus at each stage on the pathway from testing positive to hospital admission and death. The results 
confirm that alpha causes more severe outcomes, with a 73% increased hazard of death and 62% 
increased hazard of hospitalisation following a positive test in the community. These findings were 
consistent across all pre-specified sensitivity analyses, including epidemiological week of infection, 
meaning they cannot be explained by changing eligibility or external phenomena such as hospitals 
exceeding capacity. These results are in agreement with previous studies which have shown the 
alpha variant to be associated with higher case fatality in large populations selected based upon 
positive tests in the community.4-6,8,13 
By following people through the pathway of disease, we are able to describe the weakening 
association between the alpha variant and mortality as the study population is conditioned on more 
severe disease. When conditioning on hospital admission, alpha was associated with 44% increased 
hazards of death, when further conditioning on disease severe enough to require admission to ICU 
there was no evidence that alpha was associated with higher case fatality than wild type virus, 
although power for this analysis was limited and the confidence interval was consistent with the 
estimate from the full study population. 
Studies among people admitted to ICU may not provide reliable estimates of relative case fatality.  
These findings are in agreement with studies that have assessed relative case fatality of the alpha 
variant among hospitalised patients.9,14 However, there is no contradiction in the results showing 
increased mortality for alpha in the community, but no evidence of increased mortality for alpha 
among those admitted to ICU. Risk factors for death following SARS-CoV-2 infection have been 
described in detail elsewhere,15 with the predominant risk factors being older age and the presence 
of comorbidities. Conditioning on hospital admission controls for these risk factors to some extent, 
as seen by the older age and higher prevalence of comorbidities among hospitalised patients. 
Further, people admitted to ICU are a complex study population. In order to be admitted to ICU the 
attending clinician must consider the illness to be severe enough to require intensive care, but also 
that the person has a reasonable chance of survival. So people with alpha and wild type virus 
admitted to ICU may be predisposed to similar case fatality. 
It remains the case that even if there is no difference in relative mortality among people with alpha 
and wild type virus admitted to ICU, a variant that results in more people being admitted to hospital 
and ICU will have higher case fatality. 
In Frampton et al,9 which studied 341 patients hospitalised with SARS-CoV-2, no association between 
alpha and increased mortality was found. These findings support the above reasoning as their 
population was selected on acutely admitted and severely ill patients. Further, although no evidence 
of a difference in mortality risk was found, the group with the alpha variant had higher viral load, 
were younger, and had fewer comorbidities, which is consistent with a more severe disease.  
The absolute risk estimates for death and hospitalisation following a positive test presented here 
relate specifically to an unvaccinated population as they are derived from a time when vaccination 
against SARS-CoV-2 was rare and vaccination prior to infection was an exclusion criterion. These 
















the vaccination campaign on the ongoing pandemic. Recent estimates from Public Health England 
indicate that two doses of Pfizer or Oxford-AstraZeneca vaccine against SARS-CoV-2 reduce the risk 
of hospitalisation by more than 90%.16 From our data on the alpha variant, this would result in a 
reduction of the number of hospitalisations among females under the age of 40 with no 
comorbidities from 7 in 1000 to 7 in 10,000. Among males over the age of 85 with two or more 
comorbidities the reduction would be from 39 in 100 to 3.9 in 100.  
The strengths of our study include the large study population with individual-level data from primary 
care on coded diagnoses, medications, vaccinations, and physiological parameters. Linking these 
data to key datasets, such as ONS deaths data, means we have complete outcome determination for 
our study period. The main limitation of the analysis is that alpha and wild type viruses are 
determined by the SGTF proxy, which is less accurate for variant determination than sequencing. 
However, analysis indicates the sensitivity of SGTF over the study period is over 95%, and previous 
work has shown that the prevalence of SGTF in the OpenSAFELY study population is representative 
of England.6 
SGTF data are available only for people testing positive for SARS-CoV-2 in the community, as a result 
people with mild or asymptomatic infections who do not present for testing are not included, which 
may result in overestimation of the absolute risks of death and hospital admission. In addition, SARS-
CoV-2 tests performed in hospitals in England are not tested for SGTF, consequently people tested 
first in hospital, i.e. in emergency departments or on admission, are not included despite being likely 
to have more severe disease than those tested in the community.  
Our study shows that the SARS-CoV-2 alpha variant causes more severe disease than wild type virus 
following the pathway of illness from test positive to hospital admission and death. 
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Table 1 Absolute risk of death by 28-days following positive test for SARS-CoV-2, 
expressed as a percentage 
Comorbidities/Sex/Age group Wild type 
% (95% CI) 
Alpha 
% (95% CI) 
No Comorbidities   
Female: 0-<40 0.01 (0.00-0.01) 0.01 (0.00-0.02) 
40-<55 0.06 (0.04-0.08) 0.10 (0.07-0.13) 
55-<65 0.17 (0.12-0.23) 0.29 (0.21-0.38) 
65-<75 0.64 (0.45-0.83) 1.07 (0.77-1.37) 
75-<85 1.58 (1.10-2.07) 2.63 (1.85-3.41) 
85+ 3.69 (2.44-4.93) 6.03 (4.04-8.01) 
Male: 0-<40 0.02 (0.00-0.03) 0.03 (0.01-0.04) 
40-<55 0.11 (0.07-0.14) 0.18 (0.12-0.24) 
55-<65 0.32 (0.22-0.41) 0.54 (0.39-0.68) 
65-<75 1.16 (0.84-1.49) 1.94 (1.43-2.44) 
75-<85 2.85 (1.99-3.71) 4.68 (3.34-6.03) 
85+ 6.49 (4.31-8.67) 10.40 (7.08-13.72) 
1 Comorbidity   
Female: 0-<40 0.01 (0.00-0.02) 0.02 (0.01-0.04) 
40-<55 0.09 (0.06-0.13) 0.15 (0.10-0.21) 
55-<65 0.27 (0.18-0.36) 0.46 (0.31-0.60) 
65-<75 1.00 (0.72-1.28) 1.66 (1.21-2.11) 
75-<85 2.45 (1.77-3.13) 4.04 (2.94-5.13) 
85+ 5.61 (3.94-7.29) 9.05 (6.41-11.68) 
Male: 0-<40 0.02 (0.01-0.04) 0.04 (0.01-0.07) 
40-<55 0.17 (0.11-0.23) 0.28 (0.18-0.38) 
55-<65 0.50 (0.35-0.65) 0.83 (0.59-1.08) 
65-<75 1.80 (1.33-2.28) 2.99 (2.25-3.73) 
75-<85 4.36 (3.20-5.53) 7.09 (5.29-8.90) 
85+ 9.70 (6.88-12.52) 15.21 (11.04-19.38) 
2+ Comorbidities   
Female: 0-<40 0.02 (0.01-0.04) 0.04 (0.01-0.07) 
40-<55 0.17 (0.11-0.24) 0.29 (0.18-0.41) 
55-<65 0.52 (0.34-0.69) 0.86 (0.58-1.14) 
65-<75 1.87 (1.35-2.38) 3.09 (2.26-3.92) 
75-<85 4.51 (3.39-5.63) 7.33 (5.56-9.09) 
85+ 10.01 (7.47-12.55) 15.66 (11.85-19.47) 
Male: 0-<40 0.04 (0.01-0.08) 0.08 (0.02-0.13) 
40-<55 0.32 (0.20-0.44) 0.53 (0.33-0.73) 
55-<65 0.94 (0.64-1.23) 1.57 (1.09-2.04) 
65-<75 3.35 (2.50-4.19) 5.48 (4.17-6.79) 
75-<85 7.88 (6.07-9.68) 12.50 (9.80-15.20) 

















Table 2 Absolute risk of hospitalisation by 28-days following positive test for SARS-CoV-
2, expressed as a percentage 




No Comorbidities   
Female: 0-<40 0.55 (0.49-0.61) 0.74 (0.67-0.82) 
40-<55 1.45 (1.32-1.59) 1.96 (1.79-2.12) 
55-<65 2.26 (2.03-2.48) 3.02 (2.73-3.32) 
65-<75 4.16 (3.70-4.63) 5.54 (4.93-6.14) 
75-<85 5.76 (4.95-6.57) 7.61 (6.56-8.65) 
85+ 9.82 (7.97-11.67) 12.77 (10.44-15.09) 
Male: 0-<40 0.84 (0.75-0.92) 1.13 (1.01-1.24) 
40-<55 2.20 (2.01-2.39) 2.95 (2.71-3.19) 
55-<65 3.39 (3.06-3.72) 4.52 (4.11-4.94) 
65-<75 6.19 (5.51-6.86) 8.16 (7.31-9.00) 
75-<85 8.47 (7.31-9.64) 11.07 (9.60-12.54) 
85+ 14.11 (11.55-16.68) 18.07 (14.94-21.20) 
1 Comorbidity   
Female: 0-<40 1.02 (0.88-1.15) 1.37 (1.19-1.55) 
40-<55 2.67 (2.38-2.95) 3.57 (3.20-3.94) 
55-<65 4.10 (3.67-4.53) 5.45 (4.90-6.01) 
65-<75 7.43 (6.63-8.22) 9.74 (8.73-10.76) 
75-<85 10.11 (8.82-11.41) 13.13 (11.50-14.77) 
85+ 16.62 (13.84-19.40) 21.09 (17.73-24.46) 
Male: 0-<40 1.54 (1.35-1.74) 2.08 (1.81-2.34) 
40-<55 4.00 (3.59-4.41) 5.32 (4.80-5.84) 
55-<65 6.10 (5.50-6.70) 8.04 (7.29-8.79) 
65-<75 10.82 (9.74-11.90) 14.02 (12.69-15.35) 
75-<85 14.51 (12.75-16.28) 18.55 (16.40-20.70) 
85+ 23.05 (19.46-26.65) 28.64 (24.47-32.81) 
2+ Comorbidities   
Female: 0-<40 1.63 (1.39-1.87) 2.19 (1.87-2.51) 
40-<55 4.21 (3.68-4.75) 5.60 (4.90-6.30) 
55-<65 6.41 (5.64-7.18) 8.44 (7.46-9.43) 
65-<75 11.34 (10.10-12.59) 14.67 (13.11-16.22) 
75-<85 15.18 (13.41-16.95) 19.36 (17.18-21.54) 
85+ 23.99 (20.52-27.46) 29.72 (25.68-33.75) 
Male: 0-<40 2.46 (2.10-2.81) 3.29 (2.83-3.76) 
40-<55 6.26 (5.51-7.01) 8.25 (7.29-9.20) 
55-<65 9.40 (8.36-10.43) 12.24 (10.94-13.53) 
65-<75 16.17 (14.56-17.78) 20.55 (18.61-22.50) 
75-<85 21.21 (18.93-23.48) 26.51 (23.82-29.19) 

















Figure 1 Summary population characteristics for alpha and wild type infections 
a) Regional distribution of alpha cases; b) number of alpha and wild type cases by epidemiological 
week; c) number of outcomes analysed; d) age distribution (Median, IQR); e) presence of 
comorbidities 
 
Figure 2 Relative severity of alpha compared to wild type virus 
aHR: adjusted hazard ratio; ICU: intensive care unit; Death | hospital admission: death given hospital 
admission; Death | ICU: death given ICU admission. 
All models include covariate adjustment for age, sex, ethnicity, smoking status, obesity status, 
categorical number of comorbidities, index of multiple deprivation, household size, residential rural 
or urban location classification, epidemiological week, and care home status. Except for the death 
given ICU admission model, which excludes adjustment for care home status. 
Cox proportional hazards regression; all models are stratified on region by UTLA; estimating a 
separate baseline hazard function for each UTLA, with model parameters estimated by maximum 
likelihood over the full study population. 
 
Figure 3 Summary characteristics of deaths occurring with and without hospital 
admission 
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